Migraine is one of the most common disabling disorders worldwide that influence the patient functionality and quality of life. Current preventive therapy has succeeded in preventing and decreasing migraine days; however, unwanted adverse effects are considered a serious issue and can lead to discontinuation of the medication. The calcitonin-gene-related peptide is a neuropeptide that plays a major role in migraine pathogenesis, and inhibiting this peptide is thought to achieve a therapeutic role in migraine prevention. This literature review aims to review the role of this peptide in migraine pathogenesis and the implementation of monoclonal antibodies in migraine preventive therapy. A relevant articles were collected from the PubMed database, using the following Mesh words: Calcitonin-gene-related peptide, migraine, migraine prevention. Calcitonin-gene-related peptide monoclonal antibodies seem to have a significant therapeutic role in migraine prevention. Few side effects were reported, of which infection was the common reported one. The long-term safety profile has not been evaluated up to our knowledge. Therefore, a long-term safety assessment would be required in addition to comparison with the standard migraine preventive therapy.
This work is licensed under a Creative Commons Attribution 4.0 International License.
